EMBC
Embecta CorpNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$196.97M
P/E Ratio
1.76
EPS
$1.89
Beta
1.05
52W High
$15.13
52W Low
$2.77
50-Day MA
$7.45
200-Day MA
$11.38
Dividend Yield
18.10%
Profit Margin
10.70%
Forward P/E
—
PEG Ratio
—
About Embecta Corp
Embecta Corp (EMBC) is a leading medical technology company focused on revolutionizing insulin delivery systems for diabetes management. Originating as a strategic spin-off from Becton, Dickinson and Company, Embecta leverages cutting-edge technology and a comprehensive product range that includes advanced insulin pens and syringes. Committed to operational excellence and customer satisfaction, the company is poised to capitalize on growth opportunities in the dynamic diabetes care market. With its focus on improving patient outcomes and experience, Embecta is strategically positioned to enhance its leadership in this vital sector.
Fundamentals
| Revenue (TTM) | $1.04B |
| Gross Profit (TTM) | $645.50M |
| EBITDA | $332.30M |
| Operating Margin | 19.30% |
| Return on Equity | 0.00% |
| Return on Assets | 16.80% |
| Revenue/Share (TTM) | $17.74 |
| Book Value | $-10.55 |
| Price-to-Book | 2.61 |
| Price-to-Sales (TTM) | 0.19 |
| EV/Revenue | 1.314 |
| EV/EBITDA | 4.39 |
| Quarterly Earnings Growth (YoY) | 82.70% |
| Quarterly Revenue Growth (YoY) | -14.40% |
| Shares Outstanding | $59.33M |
| Float | $58.36M |
| % Insiders | 1.68% |
| % Institutions | 106.16% |
Historical Volatility
HV 10-Day
43.96%
HV 20-Day
38.43%
HV 30-Day
34.77%
HV 60-Day
34.13%
HV Rank
19.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($4.00 target)
1
Buy2
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026